ProCE Banner Activity

CE / CME

Antimicrobial Optimization in the ICU: Treating HABP/VABP in the Critically Ill Patient

Multimedia

Experts discuss the pharmacist’s role in the diagnosis, treatment, and management of MDR gram-negative infections in ICU patients with HABP and VABP.

Pharmacists : 1.00 contact {hour} ({0.1} CEUs)

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Registered Nurses : 1.00 Nursing contact {hour}

Released: May 23, 2022

Expiration: May 22, 2023

No longer available for credit.

Share

Faculty

Christopher M. Bland

Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS

Clinical Professor
Clinical and Administrative Pharmacy
University of Georgia College of Pharmacy
Clinical Pharmacy Specialist
St. Joseph’s/Candler Health System
Savannah, Georgia

Tatjana Calvano

Tatjana Calvano, DO, FACP, FIDSA

Program Director
Internal Medicine Residency
Madigan Army Medical Center
Joint Base Lewis
McChord, Washington

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Merck Sharp & Dohme Corp.

Partners

SIDP

ProCE Banner

Target Audience

The target audience is physicians, pharmacists, nurses, and other HCPs who care for critically ill patients with HABP/VABP.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the role of rapid diagnostics in HABP/VABP caused by MDR gram-negative infections
  • Appropriately use new antimicrobial agents for both empiric and targeted therapy in MDR gram-negative HABP/VABP
  • Identify strategies for managing critically ill patients with unique clinical scenarios, such as augmented or diminished renal clearance
  • Implement effective approaches to antimicrobial stewardship and minimizing TTET

Faculty Disclosure

Christopher M. Bland, PharmD, FCCP, FIDSA, BCPS, has disclosed that he has received fees for non-CME/CE services from Merck and consulting fees from Biomerieux.

Tatjana Calvano, DO, FACP, FIDSA, has no relevant conflicts of interest to report.

Staff Disclosure

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Jamie Sebaaly, PharmD, BCPS, has no relevant conflicts of interest to report.

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Instructions for Credit

Designation Statement

The Society of Critical Care Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim credit commensurate with the extent of their participation in the activity.

 

Credit Designation

The Society of Critical Care Medicine is approved by the California Board of Registered Nursing, Provider No. 8181, for 1.0 contact hour.

Credit Designation

The Society of Critical Care Medicine is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy credit. This symposium will provide 1.0 continuing education hour. Universal Activity Number - 0236-9999-23-068-H01-P.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 23, 2022, through May 22, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge and competence of HCPs about the diagnosis, treatment, and management of HABP/VABP in critically ill patients.